{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T05:32:34Z","timestamp":1782970354954,"version":"3.54.5"},"reference-count":85,"publisher":"MDPI AG","issue":"13","license":[{"start":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T00:00:00Z","timestamp":1782432000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"National Cancer Institute","award":["2P30CA016058-45"],"award-info":[{"award-number":["2P30CA016058-45"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Renal cell carcinoma (RCC) accounts for the majority of kidney cancers, with approximately 80,000 new diagnoses and over 14,000 deaths annually in the United States. Risk stratification is essential for prognostication, treatment selection, and clinical trial design across all disease stages. In localized and locally advanced RCC, pathological stage, histology, and grade remain the primary prognostic factors, while the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) criteria serve as the standard risk stratification tool in the metastatic setting. However, current models rely predominantly on clinical and pathologic variables that act as indirect surrogates of tumor biology and do not account for the molecular heterogeneity inherent to RCC. This narrative review synthesizes and compares established and emerging risk stratification and prognostic models across all stages of RCC. Established models such as the IMDC criteria and the stage, size, grade, and necrosis (SSIGN) score demonstrate robust prognostic performance but are limited by their reliance on clinical and pathologic variables alone. Emerging biomarkers\u2014including circulating tumor DNA, methylated DNA, artificial intelligence-based radiomics, and tissue-based molecular signatures\u2014show promise for improving risk discrimination. The molecular heterogeneity of RCC underscores an urgent need for integrated molecular\u2013clinical\u2013pathologic prognostic tools tailored to specific histologic subtypes to enable more precise, individualized care.<\/jats:p>","DOI":"10.3390\/cancers18132081","type":"journal-article","created":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T02:16:44Z","timestamp":1782699404000},"page":"2081","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Risk Stratification in Renal Cell Carcinoma: A Narrative Review"],"prefix":"10.3390","volume":"18","author":[{"given":"Nykiera","family":"Dixon","sequence":"first","affiliation":[{"name":"Division of Urologic Oncology, The Ohio State University Comprehensive Cancer Center, Columbus, OH 43210, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vivian","family":"Wong","sequence":"additional","affiliation":[{"name":"Division of Urologic Oncology, The Ohio State University Comprehensive Cancer Center, Columbus, OH 43210, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fuat","family":"Bicer","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, The Ohio State University Comprehensive Cancer Center, Columbus, OH 43210, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shawn","family":"Dason","sequence":"additional","affiliation":[{"name":"Division of Urologic Oncology, The Ohio State University Comprehensive Cancer Center, Columbus, OH 43210, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric A.","family":"Singer","sequence":"additional","affiliation":[{"name":"Division of Urologic Oncology, The Ohio State University Comprehensive Cancer Center, Columbus, OH 43210, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,6,26]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1158\/1055-9965.EPI-22-0784","article-title":"Associations of Renal Cell Carcinoma Subtype with Patient Demographics, Comorbidities, and Neighborhood Socioeconomic Status in the California Population","volume":"32","author":"Lichtensztajn","year":"2023","journal-title":"Cancer Epidemiol. Biomark. Prev."},{"key":"ref_2","first-page":"10","article-title":"Cancer Statistics, 2025","volume":"75","author":"Siegel","year":"2025","journal-title":"CA Cancer J. Clin."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"116","DOI":"10.4103\/0974-7796.130552","article-title":"Clinico-Pathological Prognostic Factors of Renal Cell Carcinoma: A 15-Year Review from a Single Center in Greece","volume":"6","author":"Grivas","year":"2014","journal-title":"Urol. Ann."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1002\/(SICI)1097-0142(19970901)80:5<992::AID-CNCR26>3.0.CO;2-Q","article-title":"TNM Staging of Renal Cell Carcinoma: Workgroup No. 3. Union International Contre Le Cancer (UICC) and the American Joint Committee on Cancer (AJCC)","volume":"80","author":"Guinan","year":"1997","journal-title":"Cancer"},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Greene, F.L., Page, D.L., Fleming, I.D., Fritz, A.G., Balch, C.M., Haller, D.G., and Morrow, M. (2002). AJCC Cancer Staging Manual.","DOI":"10.1007\/978-1-4757-3656-4"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1245\/s10434-010-0985-4","article-title":"The American Joint Committee on Cancer: The 7th Edition of the AJCC Cancer Staging Manual and the Future of TNM","volume":"17","author":"Edge","year":"2010","journal-title":"Ann. Surg. Oncol."},{"key":"ref_7","first-page":"93","article-title":"The Eighth Edition AJCC Cancer Staging Manual: Continuing to Build a Bridge from a Population-Based to a More \u201cPersonalized\u201d Approach to Cancer Staging","volume":"67","author":"Amin","year":"2017","journal-title":"CA Cancer J. Clin."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1097\/PAS.0b013e318299f0fb","article-title":"The International Society of Urological Pathology (ISUP) Grading System for Renal Cell Carcinoma and Other Prognostic Parameters","volume":"37","author":"Delahunt","year":"2013","journal-title":"Am. J. Surg. Pathol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1097\/00000478-198210000-00007","article-title":"Prognostic Significance of Morphologic Parameters in Renal Cell Carcinoma","volume":"6","author":"Fuhrman","year":"1982","journal-title":"Am. J. Surg. Pathol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1097\/JU.0000000000001912","article-title":"Renal Mass and Localized Renal Cancer: Evaluation, Management, and Follow-up: AUA Guideline: Part II","volume":"206","author":"Campbell","year":"2021","journal-title":"J. Urol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1016\/j.euf.2018.02.010","article-title":"Long-Term Outcomes of Follow-up for Initially Localised Clear Cell Renal Cell Carcinoma: RECUR Database Analysis","volume":"5","author":"Dabestani","year":"2019","journal-title":"Eur. Urol. Focus"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"237.e19","DOI":"10.1016\/j.urolonc.2015.11.020","article-title":"Prognosticators and Outcomes of Patients with Renal Cell Carcinoma and Adjacent Organ Invasion Treated with Radical Nephrectomy","volume":"34","author":"Borregales","year":"2016","journal-title":"Urol. Oncol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"166.e21","DOI":"10.1016\/j.urolonc.2014.11.021","article-title":"Clinically Non-Metastatic Renal Cell Carcinoma with Sarcomatoid Dedifferentiation: Natural History and Outcomes after Surgical Resection with Curative Intent","volume":"33","author":"Merrill","year":"2015","journal-title":"Urol. Oncol."},{"key":"ref_14","unstructured":"(2025, November 22). Renal Mass and Localized Renal Cancer: Evaluation, Management, and Follow Up (2021)\u2014American Urological Association. Available online: https:\/\/www.auanet.org\/guidelines-and-quality\/guidelines\/renal-mass-and-localized-renal-cancer-evaluation-management-and-follow-up."},{"key":"ref_15","first-page":"121.e15","article-title":"Comparative Prognostic Performance of KEYNOTE-564 and AUA Risk Stratification in Nonmetastatic Clear Cell Renal Cell Carcinoma","volume":"44","author":"Garofano","year":"2025","journal-title":"Urol. Oncol. Semin. Orig. Investig."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1097\/JU.0000000000004030","article-title":"Mayo Clinic Validation of the AUA Risk Groups for Localized Renal Cell Carcinoma","volume":"212","author":"Zganjar","year":"2024","journal-title":"J. Urol."},{"key":"ref_17","first-page":"443.e21","article-title":"Recurrence after Surgery for Clear Cell and Papillary Renal Cell Carcinoma: Head-to Head Comparison of Validated Risk Scores","volume":"43","author":"Longoni","year":"2025","journal-title":"Urol. Oncol. Semin. Orig. Investig."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1111\/his.13743","article-title":"Renal Cell Carcinoma Staging: Pitfalls, Challenges, and Updates","volume":"74","author":"Williamson","year":"2019","journal-title":"Histopathology"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"S33","DOI":"10.21037\/atm.2019.02.19","article-title":"Strengthening the Foundation of Kidney Cancer Treatment and Research: Revising the AJCC Staging System","volume":"7","author":"Patel","year":"2019","journal-title":"Ann. Transl. Med."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"2991","DOI":"10.1002\/cncr.32912","article-title":"Impact of Pathologic Lymph Node-Positive Renal Cell Carcinoma on Survival in Patients without Metastasis: Evidence in Support of Expanding the Definition of Stage IV Kidney Cancer","volume":"126","author":"Srivastava","year":"2020","journal-title":"Cancer"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"5431","DOI":"10.1002\/cam4.1790","article-title":"Modification of American Joint Committee on Cancer Prognostic Groups for Renal Cell Carcinoma","volume":"7","author":"Shao","year":"2018","journal-title":"Cancer Med."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"4023","DOI":"10.1002\/cncr.31661","article-title":"Renal Cell Carcinoma and Pathologic Nodal Disease: Implications for American Joint Committee on Cancer Staging","volume":"124","author":"Yu","year":"2018","journal-title":"Cancer"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1016\/j.juro.2009.05.035","article-title":"The R.E.N.A.L. Nephrometry Score: A Comprehensive Standardized System for Quantitating Renal Tumor Size, Location and Depth","volume":"182","author":"Kutikov","year":"2009","journal-title":"J. Urol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1089\/end.2011.0217","article-title":"Reproducibility and Fidelity of the R.E.N.A.L. Nephrometry Score","volume":"25","author":"Montag","year":"2011","journal-title":"J. Endourol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1007\/s00345-013-1159-3","article-title":"External Validation of the RENAL Nephrometry Score Nomogram for Predicting High-Grade Renal Cell Carcinoma in Solid, Enhancing, and Small Renal Masses","volume":"32","author":"Koo","year":"2014","journal-title":"World J. Urol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1016\/S0022-5347(05)64153-5","article-title":"An Outcome Prediction Model for Patients with Clear Cell Renal Cell Carcinoma Treated with Radical Nephrectomy Based on Tumor Stage, Size, Grade and Necrosis: The SSIGN Score","volume":"168","author":"Frank","year":"2002","journal-title":"J. Urol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1016\/S0022-5347(05)00684-1","article-title":"External Validation of the Mayo Clinic Stage, Size, Grade and Necrosis (SSIGN) Score to Predict Cancer Specific Survival Using a European Series of Conventional Renal Cell Carcinoma","volume":"175","author":"Ficarra","year":"2006","journal-title":"J. Urol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1016\/j.juro.2008.06.014","article-title":"External Validation of the Mayo Clinic Cancer Specific Survival Score in a Japanese Series of Clear Cell Renal Cell Carcinoma","volume":"180","author":"Fujii","year":"2008","journal-title":"J. Urol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.eururo.2008.11.033","article-title":"External Validation of the Mayo Clinic Stage, Size, Grade, and Necrosis (SSIGN) Score for Clear-Cell Renal Cell Carcinoma in a Single European Centre Applying Routine Pathology","volume":"57","author":"Zigeuner","year":"2010","journal-title":"Eur. Urol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/j.eururo.2016.05.034","article-title":"Application of the Stage, Size, Grade, and Necrosis (SSIGN) Score for Clear Cell Renal Cell Carcinoma in Contemporary Patients","volume":"71","author":"Parker","year":"2017","journal-title":"Eur. Urol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1093\/ajcp\/aqab136","article-title":"Prognostic Significance of Percentage Necrosis in Clear Cell Renal Cell Carcinoma","volume":"157","author":"Syed","year":"2022","journal-title":"Am. J. Clin. Pathol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1200\/JCO.2006.06.1218","article-title":"Multi-Institutional Validation of a New Renal Cancer-Specific Survival Nomogram","volume":"25","author":"Karakiewicz","year":"2007","journal-title":"J. Clin. Oncol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1200\/JCO.2001.19.6.1649","article-title":"Improved Prognostication of Renal Cell Carcinoma Using an Integrated Staging System","volume":"19","author":"Zisman","year":"2001","journal-title":"J. Clin. Oncol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"4559","DOI":"10.1200\/JCO.2002.05.111","article-title":"Risk Group Assessment and Clinical Outcome Algorithm to Predict the Natural History of Patients with Surgically Resected Renal Cell Carcinoma","volume":"20","author":"Zisman","year":"2002","journal-title":"J. Clin. Oncol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"3316","DOI":"10.1200\/JCO.2004.09.104","article-title":"Use of the University of California Los Angeles Integrated Staging System to Predict Survival in Renal Cell Carcinoma: An International Multicenter Study","volume":"22","author":"Patard","year":"2004","journal-title":"J. Clin. Oncol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1097\/01.ju.0000096049.64863.a1","article-title":"Validation of an Integrated Staging System toward Improved Prognostication of Patients with Localized Renal Cell Carcinoma in an International Population","volume":"170","author":"Han","year":"2003","journal-title":"J. Urol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1002\/cncr.21331","article-title":"Comparison of Predictive Accuracy of Four Prognostic Models for Nonmetastatic Renal Cell Carcinoma after Nephrectomy: A Multicenter European Study","volume":"104","author":"Cindolo","year":"2005","journal-title":"Cancer"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/S1470-2045(12)70559-4","article-title":"External Validation and Comparison with Other Models of the International Metastatic Renal-Cell Carcinoma Database Consortium Prognostic Model: A Population-Based Study","volume":"14","author":"Heng","year":"2013","journal-title":"Lancet Oncol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"167.e1","DOI":"10.1016\/j.urolonc.2021.11.025","article-title":"Risk of Recurrence after Nephrectomy: Comparison of Predictive Ability of Validated Risk Models","volume":"40","author":"Palumbo","year":"2022","journal-title":"Urol. Oncol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/S0022-5347(05)66077-6","article-title":"A Postoperative Prognostic Nomogram for Renal Cell Carcinoma","volume":"166","author":"Kattan","year":"2001","journal-title":"J. Urol."},{"key":"ref_41","first-page":"470.e1","article-title":"Paraneoplastic and Symptomatic Score (PRIMAL) for Prediction of Overall and Cancer-specific Survival after Surgery in Patients with Renal Cell Carcinoma","volume":"43","author":"Musso","year":"2025","journal-title":"Urol. Oncol. Semin. Orig. Investig."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"2359","DOI":"10.1245\/s10434-020-09075-4","article-title":"The SSPN Score, a Novel Scoring System Incorporating PBRM1 Expression, Predicts Postoperative Recurrence for Patients with Non-Metastatic Clear Cell Renal Cell Carcinoma","volume":"28","author":"Ohsugi","year":"2021","journal-title":"Ann. Surg. Oncol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.eururo.2021.02.025","article-title":"Predicting Disease Recurrence, Early Progression, and Overall Survival Following Surgical Resection for High-Risk Localized and Locally Advanced Renal Cell Carcinoma","volume":"80","author":"Correa","year":"2021","journal-title":"Eur. Urol."},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Klatte, T., Gallagher, K.M., Afferi, L., Volpe, A., Kroeger, N., Ribback, S., McNeill, A., Riddick, A.C.P., Armitage, J.N., and Aho, T.F. (2019). The VENUSS Prognostic Model to Predict Disease Recurrence Following Surgery for Non-Metastatic Papillary Renal Cell Carcinoma: Development and Evaluation Using the ASSURE Prospective Clinical Trial Cohort. BMC Med., 17.","DOI":"10.1186\/s12916-019-1419-1"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1016\/j.eururo.2018.01.005","article-title":"Predicting Oncologic Outcomes in Renal Cell Carcinoma After Surgery","volume":"73","author":"Leibovich","year":"2018","journal-title":"Eur. Urol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"2747","DOI":"10.1093\/annonc\/mdx492","article-title":"Validation of a New Prognostic Model to Easily Predict Outcome in Renal Cell Carcinoma: The GRANT Score Applied to the ASSURE Trial Population","volume":"28","author":"Buti","year":"2017","journal-title":"Ann. Oncol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"15330338251329848","DOI":"10.1177\/15330338251329848","article-title":"External Validation of the GRade, Age, Nodes and Tumor (GRANT) Score for Patients with Surgically Treated Papillary Renal Cell Carcinoma","volume":"24","author":"Maffezzoli","year":"2025","journal-title":"Technol. Cancer Res. Treat."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1056\/NEJMoa2106391","article-title":"Adjuvant Pembrolizumab after Nephrectomy in Renal-Cell Carcinoma","volume":"385","author":"Choueiri","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1016\/S1470-2045(22)00487-9","article-title":"Pembrolizumab versus Placebo as Post-Nephrectomy Adjuvant Therapy for Clear Cell Renal Cell Carcinoma (KEYNOTE-564): 30-Month Follow-up Analysis of a Multicentre, Randomised, Double-Blind, Placebo-Controlled, Phase 3 Trial","volume":"23","author":"Powles","year":"2022","journal-title":"Lancet Oncol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1056\/NEJMoa2312695","article-title":"Overall Survival with Adjuvant Pembrolizumab in Renal-Cell Carcinoma","volume":"390","author":"Choueiri","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"TPS4602","DOI":"10.1200\/JCO.2022.40.16_suppl.TPS4602","article-title":"LITESPARK-022: A Phase 3 Study of Pembrolizumab + Belzutifan as Adjuvant Treatment of Clear Cell Renal Cell Carcinoma (ccRCC)","volume":"40","author":"Choueiri","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"2530","DOI":"10.1200\/JCO.1999.17.8.2530","article-title":"Survival and Prognostic Stratification of 670 Patients with Advanced Renal Cell Carcinoma","volume":"17","author":"Motzer","year":"1999","journal-title":"J. Clin. Oncol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1200\/JCO.2005.05.179","article-title":"Validation and Extension of the Memorial Sloan-Kettering Prognostic Factors Model for Survival in Patients with Previously Untreated Metastatic Renal Cell Carcinoma","volume":"23","author":"Mekhail","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"3677","DOI":"10.1002\/cncr.31595","article-title":"Checkpoint Inhibitors in Patients with Metastatic Renal Cell Carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium","volume":"124","author":"Yip","year":"2018","journal-title":"Cancer"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"e267030","DOI":"10.1001\/jamanetworkopen.2026.7030","article-title":"Clinical and Molecular Validation of the Very Favorable IMDC Risk Group in Metastatic Renal Cell Carcinoma","volume":"9","author":"Zarba","year":"2026","journal-title":"JAMA Netw. Open"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.euo.2023.06.008","article-title":"The Selection for Cytoreductive Nephrectomy (SCREEN) Score: Improving Surgical Risk Stratification by Integrating Common Radiographic Features","volume":"7","author":"Abel","year":"2024","journal-title":"Eur. Urol. Oncol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1097\/CCO.0000000000001138","article-title":"Biomarkers in Advanced Renal Cell Carcinoma: Current Practice and Future Directions","volume":"37","author":"Wong","year":"2025","journal-title":"Curr. Opin. Oncol."},{"key":"ref_58","doi-asserted-by":"crossref","unstructured":"Zheng, X., Lin, J., Xiong, J., Guan, Y., Lan, B., Li, Y., Gao, X., Fei, Z., Chen, L., and Chen, L. (2023). SETD2 Variation Correlates with Tumor Mutational Burden and MSI along with Improved Response to Immunotherapy. BMC Cancer, 23.","DOI":"10.1186\/s12885-023-10920-4"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"e2200407","DOI":"10.1200\/PO.22.00407","article-title":"Adjuvant Therapy for Renal Cell Carcinoma: End Points, Outcomes, and Risk Assessments","volume":"7","author":"Boyle","year":"2023","journal-title":"JCO Precis. Oncol."},{"key":"ref_60","doi-asserted-by":"crossref","unstructured":"Sproston, N.R., and Ashworth, J.J. (2018). Role of C-Reactive Protein at Sites of Inflammation and Infection. Front. Immunol., 9.","DOI":"10.3389\/fimmu.2018.00754"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1007\/s12672-024-01071-4","article-title":"Dynamic Changes of SCGN Expression Imply Different Phases of Clear Cell Renal Cell Carcinoma Progression","volume":"15","author":"Guo","year":"2024","journal-title":"Discov. Oncol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1007\/s00432-024-05803-5","article-title":"Tumor Infiltrating B Lymphocytes (TIBs) Associate with Poor Clinical Outcomes, Unfavorable Therapeutic Benefit and Immunosuppressive Context in Metastatic Clear Cell Renal Cell Carcinoma (mccRCC) Patients Treated with Anti-PD-1 Antibody plus Axitinib","volume":"150","author":"Lin","year":"2024","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.1007\/s10147-024-02593-1","article-title":"Prognostic Significance of Inflammatory Markers in Patients with Advanced Renal Cell Carcinoma Receiving Nivolumab plus Ipilimumab","volume":"29","author":"Nakayama","year":"2024","journal-title":"Int. J. Clin. Oncol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1186\/s12957-020-02046-9","article-title":"A Risk Stratification Model Based on Four Novel Biomarkers Predicts Prognosis for Patients with Renal Cell Carcinoma","volume":"18","author":"Kubota","year":"2020","journal-title":"World J. Surg. Oncol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1038\/s41416-025-03008-2","article-title":"A Prognostic microRNA-Based Signature for Localized Clear Cell Renal Cell Carcinoma: The Bio-miR Study","volume":"133","author":"Vasudev","year":"2025","journal-title":"Br. J. Cancer"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"3397","DOI":"10.1158\/1078-0432.CCR-21-0025","article-title":"Plasma KIM-1 Is Associated with Recurrence Risk after Nephrectomy for Localized Renal Cell Carcinoma: A Trial of the ECOG-ACRIN Research Group (E2805)","volume":"27","author":"Xu","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1038\/s41591-025-04067-x","article-title":"Soluble MAdCAM-1 as a Biomarker in Metastatic Renal Cell Carcinoma","volume":"32","author":"Machaalani","year":"2026","journal-title":"Nat. Med."},{"key":"ref_68","unstructured":"(2026, May 03). Real-World Trends in Costs of next Generation Sequencing (NGS) Testing in U.S. Setting\u2014ASCO. Available online: https:\/\/www.asco.org\/abstracts-presentations\/199638."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"e255785","DOI":"10.1001\/jamanetworkopen.2025.5785","article-title":"Claim Denials for Cancer-Related Next-Generation Sequencing in Medicare","volume":"8","author":"Kang","year":"2025","journal-title":"JAMA Netw. Open"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1016\/j.annonc.2023.06.011","article-title":"ESMO Study on the Availability and Accessibility of Biomolecular Technologies in Oncology in Europe","volume":"34","author":"Bayle","year":"2023","journal-title":"Ann. Oncol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1158\/1078-0432.CCR-23-1892","article-title":"Management of Renal Cell Carcinoma: Promising Biomarkers and the Challenges to Reach the Clinic","volume":"30","author":"Iisager","year":"2024","journal-title":"Clin. Cancer Res."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/j.urolonc.2025.07.020","article-title":"Developing Biomarkers and Methods of Risk Stratification: Consensus Statements from the International Kidney Cancer Symposium North America 2024 Think Tank","volume":"43","author":"Shapiro","year":"2025","journal-title":"Urol. Oncol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1016\/j.euf.2025.05.023","article-title":"Life Expectancy of Renal Cell Carcinoma with Variant Histology","volume":"11","author":"Le","year":"2025","journal-title":"Eur. Urol. Focus"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.urolonc.2024.02.003","article-title":"The New WHO Category of \u201cMolecularly Defined Renal Carcinomas\u201d: Clinical and Diagnostic Features and Management Implications","volume":"42","author":"Kanakaraj","year":"2024","journal-title":"Urol. Oncol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1111\/his.70008","article-title":"Renal Cell Tumours with Papillary Architecture: Evolving Concepts, Classification and New Emerging Entities","volume":"88","author":"Alruwaii","year":"2026","journal-title":"Histopathology"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1111\/his.14700","article-title":"WHO 2022 Landscape of Papillary and Chromophobe Renal Cell Carcinoma","volume":"81","author":"Lobo","year":"2022","journal-title":"Histopathology"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1038\/s41379-021-00779-w","article-title":"New Developments in Existing WHO Entities and Evolving Molecular Concepts: The Genitourinary Pathology Society (GUPS) Update on Renal Neoplasia","volume":"34","author":"Trpkov","year":"2021","journal-title":"Mod. Pathol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1093\/jjco\/hyag023","article-title":"Risk Stratification by Pathological Upstaging and Tumor Necrosis in Clinical T1 Clear-Cell Renal Cell Carcinoma: Evidence from a Multi-Institutional Cohort of 1081 Patients","volume":"56","author":"Ueki","year":"2026","journal-title":"Jpn. J. Clin. Oncol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.ejca.2022.03.023","article-title":"Pathological and Genetic Markers Improve Recurrence Prognostication with the University of California Los Angeles Integrated Staging System for Patients with Clear Cell Renal Cell Carcinoma","volume":"168","author":"Kroeger","year":"2022","journal-title":"Eur. J. Cancer"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.eururo.2023.04.003","article-title":"Current Landscape of Genomic Biomarkers in Clear Cell Renal Cell Carcinoma","volume":"84","author":"Cotta","year":"2023","journal-title":"Eur. Urol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"4","DOI":"10.6004\/jnccn.2024.0008","article-title":"NCCN Guidelines\u00ae Insights: Kidney Cancer, Version 2.2024","volume":"22","author":"Motzer","year":"2024","journal-title":"J. Natl. Compr. Cancer Netw. JNCCN"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/S1470-2045(14)71222-7","article-title":"The International Metastatic Renal Cell Carcinoma Database Consortium Model as a Prognostic Tool in Patients with Metastatic Renal Cell Carcinoma Previously Treated with First-Line Targeted Therapy: A Population-Based Study","volume":"16","author":"Ko","year":"2015","journal-title":"Lancet Oncol."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1016\/j.eururo.2016.09.047","article-title":"Efficacy of Second-Line Targeted Therapy for Renal Cell Carcinoma According to Change from Baseline in International Metastatic Renal Cell Carcinoma Database Consortium Prognostic Category","volume":"71","author":"Davis","year":"2017","journal-title":"Eur. Urol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1093\/jjco\/hyaf018","article-title":"Validation of Five Prognostic Models Treated with Axitinib beyond First-Line Nivolumab plus Ipilimumab Therapy for Metastatic Renal Cell Carcinoma: A Japanese Multicenter Retrospective Study","volume":"55","author":"Kikuchi","year":"2025","journal-title":"Jpn. J. Clin. Oncol."},{"key":"ref_85","doi-asserted-by":"crossref","unstructured":"Matsuyama, N., Hara, T., Ueki, H., Wakita, N., Okamura, Y., Bando, Y., Suzuki, K., Terakawa, T., Chiba, K., and Yao, A. (2026). Prognostic Significance of Early Tumor Shrinkage in Metastatic Renal Cell Carcinoma Treated with First-Line Immune Checkpoint Inhibitor-Based Combination Therapy. Int. J. Clin. Oncol.","DOI":"10.21203\/rs.3.rs-8567777\/v1"}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/13\/2081\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T04:16:57Z","timestamp":1782965817000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/13\/2081"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,26]]},"references-count":85,"journal-issue":{"issue":"13","published-online":{"date-parts":[[2026,7]]}},"alternative-id":["cancers18132081"],"URL":"https:\/\/doi.org\/10.3390\/cancers18132081","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,26]]}}}